Switch theme
Sign up to access all valuation multiples
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
2019
46
LTM Revenue $1K
LTM EBITDA -$111M
$773M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Enliven Therapeutics has a last 12-month revenue of $1K and a last 12-month EBITDA of -$111M.
In the most recent fiscal year, Enliven Therapeutics achieved revenue of n/a and an EBITDA of -$83.2M.
Enliven Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Enliven Therapeutics valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | $1K | XXX |
| Gross Profit | n/a | n/a | n/a | XXX | XXX |
| Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
| EBITDA | -$38.6M | -$83.2M | -$106M | -$111M | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | -Infinity% | -9047621% | XXX |
| Net Profit | -$24.7M | -$37.7M | -$71.6M | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | -Infinity% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Enliven Therapeutics's stock price is $22.
Enliven Therapeutics has current market cap of $1.1B, and EV of $773M.
See Enliven Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $773M | $1.1B | XXX | XXX | XXX | XXX | $-2.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Enliven Therapeutics has market cap of $1.1B and EV of $773M.
Enliven Therapeutics's trades at 629016.4x LTM EV/Revenue multiple, and -7.0x LTM EBITDA.
Analysts estimate Enliven Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Enliven Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $773M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -7.3x | XXX | XXX | XXX |
| P/E | -12.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEnliven Therapeutics's NTM/LTM revenue growth is 598%
Enliven Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.8M for the same period.
Over next 12 months, Enliven Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Enliven Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Enliven Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Enliven Therapeutics acquired XXX companies to date.
Last acquisition by Enliven Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Enliven Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Enliven Therapeutics founded? | Enliven Therapeutics was founded in 2019. |
| Where is Enliven Therapeutics headquartered? | Enliven Therapeutics is headquartered in United States of America. |
| How many employees does Enliven Therapeutics have? | As of today, Enliven Therapeutics has 46 employees. |
| Who is the CEO of Enliven Therapeutics? | Enliven Therapeutics's CEO is Mr. Sam Kintz, M.B.A.. |
| Is Enliven Therapeutics publicy listed? | Yes, Enliven Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Enliven Therapeutics? | Enliven Therapeutics trades under ELVN ticker. |
| When did Enliven Therapeutics go public? | Enliven Therapeutics went public in 2023. |
| Who are competitors of Enliven Therapeutics? | Similar companies to Enliven Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Enliven Therapeutics? | Enliven Therapeutics's current market cap is $1.1B |
| What is the current revenue of Enliven Therapeutics? | Enliven Therapeutics's last 12-month revenue is $1K. |
| What is the current EBITDA of Enliven Therapeutics? | Enliven Therapeutics's last 12-month EBITDA is -$111M. |
| What is the current EV/Revenue multiple of Enliven Therapeutics? | Current revenue multiple of Enliven Therapeutics is 629016.4x. |
| What is the current EV/EBITDA multiple of Enliven Therapeutics? | Current EBITDA multiple of Enliven Therapeutics is -7.0x. |
| Is Enliven Therapeutics profitable? | Yes, Enliven Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
